OpenScience.ink

3 weeks ago • eLife

The Crunchometer: An inexpensive, open tool to analyze detailed chewing soundsThe Crunchometer, a low-cost, open-source acoustic analysis of feeding microstructure.

🥈 Top 2% Journal

3 weeks ago • Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Cancer risk of weight-loss drugs that activate the glucagon-like peptide-1 receptor compared to bariatric surgery and other treatmentsCancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.

📖 Top 20% Journal

3 weeks ago • Nature reviews. Endocrinology

How Fat Detection and Brain Hormones Influence Eating and Blood Sugar ControlLipid sensing and brain hormone receptors in food intake and glucose regulation.

🥇 Top 1% Journal

3 weeks ago • Diabetes

How GIP Medicine Affects Insulin, Glucagon, and Heart Responses During High Blood Sugar in Type 2 DiabetesEffects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes.

🥉 Top 5% Journal

3 weeks ago • World journal of surgery

Use of GLP-1 Receptor Agonists Around Breast Cancer Surgery and 30-Day Recovery OutcomesPerioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study.

📖 Top 30% Journal

3 weeks ago • Cureus

Sudden Small Intestine Blockage Linked to Tirzepatide (Mounjaro)Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro).

3 weeks ago • Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

Long-term heart health benefits of weight-loss surgery compared to drug treatments in people with type 2 diabetes and obesityThe long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.

📖 Top 20% Journal

3 weeks ago • Annals of internal medicine

Glucagon-like Peptide-1 Receptor Agonists and Risk of Front Eye Nerve Damage: A Nationwide StudyGlucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.

🥈 Top 2% Journal

3 weeks ago • Cells

Liraglutide Strongly Protects Pancreatic Cells from Injury Linked to Blocking HMGB1 ReleaseLiraglutide Potently Protects Against Streptozotocin-Induced Islet Injury Associated with Inhibition of HMGB1 Release.

🎖️ Top 10% Journal

3 weeks ago • Translational psychiatry

Effects of activating the glucagon-like peptide-1 receptor on mental health using genetic analysisGlucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study.

🥉 Top 5% Journal

3 weeks ago • Endocrine

Comparing IDegLira and insulin glargine in short-term intensive treatment for overweight or obese type 2 diabetes patientsComparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.

3 weeks ago • JBRA assisted reproduction

What We Know About How GLP-1 Receptor Agonists Affect FertilityGLP-1 Receptor Agonists and Fertility: What Is Known So Far?

📖 Top 50% Journal

3 weeks ago • Journal of gastroenterology and hepatology

Comparing Combined GLP-1 and SGLT2 Treatments to Single Therapy in Fatty Liver Disease and Type 2 DiabetesGLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.

📖 Top 20% Journal

3 weeks ago • Journal of evidence-based medicine

Stopping Diabetes Drugs That Activate GLP-1 Receptors After Bowel Blockage or Intestinal Paralysis: A Large Real-World StudyDiscontinuation of Glucagon-Like Peptide-1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real-World, Database Study.

📖 Top 20% Journal

3 weeks ago • Diabetes research and clinical practice

Tirzepatide and its links to heart health and death rates in people with obesity and diabetesTirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.

🎖️ Top 10% Journal

3 weeks ago • Obesity pillars

Changes in food cravings, diet quality, body weight, and eating habits during treatment with GLP-1 receptor medicinesChanges in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.

📖 Top 20% Journal

3 weeks ago • Journal of endocrinological investigation

Comparing the effects of injected GLP-1 drugs and SGLT2 inhibitors on metabolism and liver health in type 2 diabetes with fatty liverComparative effectiveness of subcutaneous GLP-1 receptor agonists versus SGLT2 inhibitors on metabolic and hepatic outcomes in T2DM with MASLD: a propensity score-matched study.

📖 Top 20% Journal

3 weeks ago • Endocrine reviews

New types of diabetes drugs for heart, kidney, and metabolism healthNewer and novel antidiabetic drug classes across the cardiovascular-kidney-metabolic continuum.

🥇 Top 1% Journal

3 weeks ago • Diabetes, obesity & metabolism

Safety of Tirzepatide in Everyday Medical Use Based on Reported Side EffectsSafety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.

3 weeks ago • A&A practice

Severe Lactic Acidosis and High Blood Sugar After Surgery Improving with Thiamine in a Patient Using Semaglutide and Following a Restrictive DietSevere Perioperative Lactic Acidosis and Hyperglycemia Responsive to Thiamine in a Patient With Prior Semaglutide Use and Restrictive Dieting: A Case Report.

3 weeks ago • Annals of internal medicine

How Well Glucagon-like Peptide-1 Receptor Agonists Work Compared to Oral Medicines for Stopping Insulin in Type 2 DiabetesComparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.

🥈 Top 2% Journal

3 weeks ago • Diabetes, obesity & metabolism

Kidney Problems Do Not Change How Zenagamtide Is Processed or Its Safety and TolerabilityRenal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.

3 weeks ago • Acta diabetologica

Long-lasting blood sugar control with semaglutide treatment in an adult with latent autoimmune diabetes and multiple autoimmune conditions: a case report and reviewSustained metabolic control in latent autoimmune diabetes in adults (LADA) with semaglutide therapy in a patient with multiple autoimmune comorbidities: a case report and literature review.

3 weeks ago • Annals of internal medicine

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Blood Flow Blockage in the Optic Nerve: A Target Trial EmulationGlucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.

🥈 Top 2% Journal

3 weeks ago • Diabetes, obesity & metabolism

How Adults in Denmark Use Semaglutide for Weight Loss and What Effects They ExperienceTreatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.

3 weeks ago • CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Heart and kidney outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus single treatments in type 2 diabetesCardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis.

📖 Top 20% Journal

3 weeks ago • The International journal of pharmacy practice

Community pharmacists' views and experiences with GLP-1 drugs for managing obesity in IrelandCommunity pharmacists' experiences and perspectives on GLP-1 receptor agonists for obesity management: a cross-sectional study in Ireland.

📖 Top 50% Journal

3 weeks ago • Obesity (Silver Spring, Md.)

How Incretin-Like Treatments May Affect Muscle and Bone Health in Older AdultsThe Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.

🎖️ Top 10% Journal

3 weeks ago • Obesity pillars

Reasons for starting tirzepatide and experiences among people with obesity or overweightUnderstanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.

📖 Top 20% Journal

3 weeks ago • Cardiovascular diabetology

Heart health outcomes of combining empagliflozin and GLP-1RA in type 2 diabetesCardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.

🥈 Top 2% Journal

← prevpage 11 of 15next →

Latest GLP-1 Therapies Research Papers